These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1723583)

  • 21. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of prostate-specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate.
    Presti JC; Carroll PR
    Semin Urol Oncol; 1996 Aug; 14(3):134-8. PubMed ID: 8865474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
    Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
    J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mass screening for prostate cancer in Nagano].
    Ishizuka O; Satoh T; Kobayashi S; Nishizawa O
    Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.
    Smith DS; Humphrey PA; Catalona WJ
    Cancer; 1997 Nov; 80(9):1852-6. PubMed ID: 9351559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Underutilization of digital rectal examination when screening for prostate cancer.
    Murthy GD; Byron DP; Pasquale D
    Arch Intern Med; 2004 Feb; 164(3):313-6. PubMed ID: 14769627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ; Zappa M; Määttänen L; Ciatto S
    Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study shows PSA better than DRE in screening for prostate cancer.
    Oncology (Williston Park); 1991 Nov; 5(11):36. PubMed ID: 1722420
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
    Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
    BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economics of screening for carcinoma of the prostate.
    Optenberg SA; Thompson IM
    Urol Clin North Am; 1990 Nov; 17(4):719-37. PubMed ID: 1699340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The "hook effect": high concentrations of prostate-specific antigen giving artifactually low values on one-step immunoassay.
    Wolf BA; Garrett NC; Nahm MH
    N Engl J Med; 1989 Jun; 320(26):1755-6. PubMed ID: 2471931
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostatic specific antigen in prostate cancer.
    Wozniak-Petrofsky J
    Urol Nurs; 1992 Sep; 12(3):104-5. PubMed ID: 1382317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.